Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$24.76 – $26.09
10% from low
Exchange
BATS
ETF
Borrow rate
3.28%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $355.0K | $22.5M | $73.0M | $85.6M |
| Cost of revenue | $0 | $0 | $0 | $0 | $4.0K | $7.3M | $10.0M | $19.2M |
| Gross profit | $0 | $0 | $0 | $0 | $351.0K | $15.2M | $63.0M | $66.3M |
| Gross margin | — | — | — | — | 98.9% | 67.4% | 86.3% | 77.5% |
| R&D | $11.1M | $17.9M | $32.7M | $41.3M | $51.2M | $53.1M | $69.6M | $54.3M |
| Operating income | −$17.8M | −$27.0M | −$46.1M | −$69.8M | −$129.7M | −$159.2M | −$136.3M | −$93.0M |
| EBITDA | −$17.7M | −$26.8M | −$45.5M | −$69.0M | −$124.2M | −$152.2M | −$130.3M | −$89.8M |
| Net income | −$18.2M | −$27.3M | −$46.3M | −$71.9M | −$137.5M | −$169.7M | −$149.8M | −$113.7M |
| Net margin | — | — | — | — | -38727.0% | -753.2% | -205.3% | -132.9% |
| EPS (diluted) | -1.23 | -1.97 | -2.15 | -2.84 | -4.16 | -4.49 | -3.93 | -2.66 |
Annual figures · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| FLXNHorizon Flexible Income ETF | $24.93 | +0.18% | $493764 | — |
| BULXGraniteShares 2x Long BULL Daily ETF | $2.96 | +0.00% | $97041 | — |
| CPXRUSCF Daily Target 2X Copper Index ETF | $29.08 | +2.41% | $664711 | — |
| EMGCEmerge EMPWR Sustainable Select Growth Equity ETF | $24.48 | +0.00% | $500375 | — |
| ESLGEventide Large Cap Growth ETF |
No company description on file.
No one on the platform currently holds FLXN.
No tracked institution reports a position in FLXN as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-29 | $0.2238 | 2026-06-30 |
| 2026-05-28 | $0.1898 | 2026-05-29 |
| 2026-04-27 | $0.6828 | 2026-04-28 |
| 2026-02-27 | $0.1149 | 2026-03-02 |
| 2025-12-24 | $0.7393 | 2025-12-26 |
| 2025-08-22 | $0.1458 | 2025-08-25 |
No one on the platform has traded FLXN yet.
| $28.73 |
| +1.62% |
| $569400 |
| — |
| ESLVEventide Large Cap Value ETF | $28.67 | +0.40% | $576238 | — |
| ETRLGraniteShares 2x Long ETOR Daily ETF | $12.58 | +0.04% | $420637 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Highest Volume Rated ETFs Per 12/9/2025’s Close: 1 – $CIL 2 – $TMAR 3 – $BMDL 4 – $DWUS 5 – $FLXN 6 – $HBTA 7 – $TGRW 8 – $LLDR 9 – $MCDS 10 – $JHMD https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-12-9-2025/
View on StockTwits ↗$FLXN was the first stock I ever bought back in 2015 and looks like nothing changed in 9 years. Its at the same fucking price 😓
View on StockTwits ↗$FLXN modernworldnews.com - Flexion Therapeutics is a biopharmaceutical company focused on developing innovative solutions for musculoskeletal disorders. Why did the skeleton refuse to go to the party? He had nobody to dance with! Flexion Therapeutics could have a bone-rattling good run in the future.
View on StockTwits ↗$CYDY Held a couple biotechs into FDA catalysts. Both $PTLA and $FLXN went down in the days prior to a positive FDA outcome. On the flipside also been in a few that ramped into Fda catalysts only to see a negative outcome. This is nothing but a buying opportunity, I expect a great conference call. King Cyrus the Great is about to free us from the evils of FDA Babylon. Extremely
View on StockTwits ↗@Rise2top big pharma can also wait until stock bleeds or there sales ramp is slower than expected. 99% of bios struggle going a lone without a partner. $sgyp $flxn $auph $KRTX
View on StockTwits ↗$FLXN BUY/SELL METER Alert Cross 18% +- Technical Analysis https://t8sk.com/FLXN
View on StockTwits ↗$FLXN [15s. delayed]: Issued Press Release on June 15, 08:00:00: Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Office https://s.flashalert.me/W3hMem
View on StockTwits ↗$FLXN Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer https://www.stocktitan.net/news/FLXN/avilar-therapeutics-appoints-adam-muzikant-ph-d-as-chief-business-mkthdj7joguy.html
View on StockTwits ↗$FLXN Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer https://newsfilter.io/a/f0858fd0e1d7e3f0c1e10c15595de57f
View on StockTwits ↗$FLXN - Calls open interest is downshifting for Flexion Therapeutics this week https://www.macroaxis.com/stock-options/FLXN/Flexion-Therapeutics?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$FLXN TA Stats Today's Change 18% + 🚀 https://t8sk.com/FLXN
View on StockTwits ↗$FLXN TA Stats Today's Change 11% + 🚀 https://t8sk.com/FLXN
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.